Home/Pipeline/itMSCs + itNSCs

itMSCs + itNSCs

Ischemic Stroke

ResearchActive

Key Facts

Indication

Ischemic Stroke

Phase

Research

Status

Active

Company

Stemedica Cell Technologies

About Stemedica Cell Technologies

Stemedica is a private, clinical-stage biotech company specializing in allogeneic progenitor cell therapies manufactured using its proprietary low-oxygen BioSmart Technology™ platform. The company's pipeline is anchored by ischemia-tolerant mesenchymal stem cells (itMSCs) in Phase IIb/III trials for chronic ischemic stroke and earlier development for Alzheimer's, alongside ischemia-tolerant neural progenitor cells (itNSCs) for spinal cord injury. With a cGMP-licensed manufacturing facility and a robust IP portfolio, Stemedica aims to address significant unmet needs in neurology, though it faces the inherent risks of clinical development and a competitive cell therapy landscape.

View full company profile

Therapeutic Areas

Neurology Cardiovascular

Other Ischemic Stroke Drugs

Drug	Company	Phase	Status
dl-3-n-Butylphthalide (NBP) Soft Capsules	cspc-pharmaceutical	Phase 3	Active (US trials with FDA orphan drug designation)
MultiStem	Athersys	Phase 3	Active (subject to funding)
IQool™ System	BrainCool	Clinical Evaluation	Evidence Generation
BXT-25	BioXyTran	Preclinical	Active
Ischemic Stroke Program	CHS Pharma	Pre-clinical	Active
3K3A-APC	ZZ Biotech	Phase 2/3	Active
Ischemic Stroke Device(s)	Infinity Neuro	Pre-clinical	Active
THDG3	DeckTherapeutics	Pre-clinical	Active
Prometheus-based Gene Therapy	Remedium Bio	Pre-clinical	Active
iNstroke Catheters	iVascularU	Commercial	Active
Dual Thrombolytic Regimen (tPA + HisproUK)	Thrombolytic Science International	Phase 2	Active
Neural Stem Cell Therapy for Stroke	Neoneuron	Pre-clinical	Active